NZVC — 2024 Investments

1 investments dated 2024 · listed companies and verified rows first · show all

Siren Biotechnologysirenbiotechnology.comin 𝕏Apr 2024

Siren Biotechnology develops next-generation AAV (adeno-associated virus) platforms for gene therapy applications, including gene repair, gene transfer, and gene editing.

BiotechDigital HealthMedical DevicesSan Francisco, US

Dr. Nicole Paulk(CEO, Founder, and President)Sharon Tetlow(Director)Brad Allen(Director)Nicole Paulk(Executive Officer, Director)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.